MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:32Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Insulins]]
			[[Category:Rapid-acting insulins]]
			[[Category:Mealtime insulins]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #102

2026-05-23T03:46:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #102

New page

{{MedTemplate
| generic = Insulin aspart
| brand = NovoLog, Fiasp (ultra-rapid), Trurapi
| structure =
| classes = [[:Category:Insulins|Insulin]], [[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]], [[:Category:Mealtime_insulins|Mealtime (bolus) insulin]]
| uses = <vote slug="type1-diabetes-use">Type 1 diabetes mellitus (mealtime)</vote>, <vote slug="type2-diabetes-prandial-use">Type 2 diabetes mellitus (mealtime)</vote>, <vote slug="dka-hhs-use">DKA / HHS (IV infusion)</vote>
| starting_dose = SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose
| preparations = 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges
| fda_max = Titrated to glucose; no fixed maximum
| pill_id =
| routes = Subcutaneous, IV, insulin pumps
| onset = SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average)
| duration = 3-5 hours
| halflife = ~80 minutes SC<ref name="novolog-label">FDA Prescribing Information, NovoLog (insulin aspart), Novo Nordisk, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020986s085lbl.pdf</ref>
| bioavailability = ~100% from subcutaneous depot
| pregnancy = Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="aspart-mech-claim">Insulin aspart is a recombinant human insulin analog with B28-Pro replaced by aspartate; the substitution reduces hexamer stability, so injected insulin dissociates to monomer rapidly and absorbs in time for a meal-timed dose.</vote> Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Fiasp formulation adds niacinamide and L-arginine to accelerate the initial absorption phase further, allowing dosing at meal start (or up to 20 minutes after)<ref name="novolog-label" />.
}}

== References ==
<references />

Insulin Aspart - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #102